drugset / Trial / NCT00245271
Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction
RandomizedParallel-groupQuadruple-blindTreatment
Summary
OMS103HP is being developed for improvement in knee function following ACL reconstruction. Secondary benefits being evaluated include reduced postoperative pain, improvement in knee motion and earlier return to work.
Timeline
- Start
- 2004-10
- Primary completion
- 2010-03
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OMS103HP | Other / unclassified | — | Other |
Indications
No indication recorded.